

Medibio Limited enters into MOU with Preventice Solutions

A leading US provider of remote monitoring products and services

Sydney, Australia – 28 May 2015: Medibio Ltd (MEB or the **Company**) is pleased to announce that it has entered into an MOU with **Preventice Solutions (Preventice Inc.)**.

Preventice Solutions is a strategic combination of: eCardio Diagnostics[®] LLC, a leading provider of remote cardiac monitoring products and services and Preventice, an innovator in software solutions for remote patient care and developer of the PatientCare Platform and the BodyGuardian[®] Remote Monitoring Sensor. The two US companies operate as wholly-owned subsidiaries of a newly formed holding company, Preventice Inc. The Merck Global Health Innovation Fund (GHIF) is the primary shareholder of Preventice Solutions.

The BodyGuardian's heart sensor, manufactured by Preventice, is the first small size comfortable, light weight, non-intrusive wearable sensor, that delivers best continuity of care and provides continuous 24-hour near real-time cardiac monitoring. Preventice's PatientCare Platform was initially designed for the remote monitoring of cardiac arrhythmia patients. Its monitoring system is a cutting edge approach to patient monitoring that allows physicians to monitor a patient's physiologic data. The BodyGuardian wirelessly transmits ECG and other physiological data to Preventice's mHealth PatientCare platform, where it can be securely viewed anytime, anywhere online, or stored for later retrieval.

Preventice Solution's health data platform is ideal for the commercial delivery of Medibio's Circadian Heart Rate tests to assist clinicians with the diagnosis of depression, workplace stress, and other mental health disorders. Additionally, Preventice Solutions has significant infrastructure in the US including an end to end sales and distribution chain to providers and leading medical organisations and a 24/7 patient call centre which could potentially be leveraged by Medibio.

Preventice Solutions products and services include:

- FDA and CE Mark approved next generation cardiac monitors which collect and transmit ECG data wirelessly in near real time.
- A research and development centre that leverages the emerging power of smartphones in medical applications.
- A remote monitoring platform for data collection, processing algorithms and near real time delivery of data and results to hospitals, medical professionals, and patients.
- A 24/7 patient call centre.
- An end to end sales and distribution chain to providers and leading medical organisations in the US.

The MOU provides a framework for how both parties could collaborate which may lead towards a Strategic Partnership Agreement. The MOU outlines the contemplated aspects of a Definitive Agreement.

ABOUT PREVENTICE SOLUTIONS

Preventice Solutions is a strategic combination of eCardio and Preventice. Together, we are designing the industry’s superior customer service experience. Using patient and physician insights to create revolutionary monitoring technologies and services that connect patients and caregivers in a way that redefines what healthcare can be. Operating and corporate functions will be managed from eCardio’s existing corporate headquarters in Houston while the clinical research and product development activities will remain at Preventice’s Rochester, Minn., location. eCardio’s two Independent Diagnostic Testing Facilities will continue to monitor patients from Houston and South San Francisco. eCardio Diagnostics, LLC and Boost Information Systems, Inc. doing business as Preventice are independent, wholly owned subsidiaries of Preventice, Inc.

End

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This test utilizes circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression, other mental health disorders and chronic stress. The technology consists of a heart monitor that sends ECG recordings wirelessly to the internet where a proprietary algorithm analyses and delivers a quantifiable measure which can be used by a clinician to assist in diagnosis. The Technology has the potential to be the first FDA Approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. The technology has already benefited from 10 years of laboratory research and Medibio is undertaking a number of pivotal studies to validate its clinical utility.

Further Information:		Website: www.medibio.com.au www.ecardio.com www.preventicesolutions.com
<p>Medibio Shareholder Enquiries to: Dr Matt Mesnik Chief Medical Officer Medibio Limited matt.mesnik@medibio.com.au T: +1 736 670 4265 <i>Note - as Matt is based in USA he will be available until 3pm EST</i></p>	<p>Medibio Media Enquiries to: Peter Taylor NWR Communications Peter@nwrcommunications.com.au T: +61 (0)412 036 231</p>	
<p>Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885 979</p>	<p>Preventice Solutions Enquiries to Paul Davis Senior Vice President - Sales, Marketing & Services. Office: +1-281-760-0500 Pdavis@preventice.com</p>	